2024 - Enhanced Multiplex IHC Technology for Precision Oncology

Unlock the potential of cutting-edge technology in oncology research. Dive into the latest breakthroughs in multiplex immunohistochemistry (IHC) during this upcoming webinar about Veracyte’s Brightplex® technology, a prominent example of multiplex IHC advancements. This webinar will explore innovative features that elevate the capabilities of this technology, providing a deeper understanding of not only the tumor microenvironment (TME) but also the critical imperative for biomarkers in the context of clinical trials.
Brightplex new features incorporate in situ hybridization (ISH) probes for the detection of RNA transcripts alongside traditional multiplex IHC biomarkers. This innovative approach allows the simultaneous detection of several protein expressions and RNA transcripts, facilitating a more complete understanding of the complex molecular dynamics within the TME. The technology is particularly relevant when no or poor antibodies are available for a specific target. Complex cell phenotypes can still be analyzed by combining RNA transcripts and proteins. The featured speakers will showcase how this multimodal technology can significantly enhance biomarker studies.
Read more...
Join this webinar where experts will walk attendees through the strengths of Veracyte’s Brightplex technology and how their team can help your organization uncover insights on the underlying mechanisms of therapy response and resistance at the individual and cohort level.
Keywords: IHC Assays, Precision Oncology, Immune-Oncology, Digital Pathology, Multiplex Immunohistochemistry, Translational Research, Translational Medicine, Immunohistochemistry, Tumor Microenvironment, Diagnostics,  Biomarker Discovery, IHC, Cancer,  IHC Assay,  CDx, Companion Diagnostics, Cancer Research, Biomarkers, Oncology, Clinical Research, Immuno-Oncology, Precision Medicine, Drug Development